Changes in Hong Kong stocks | Boan Biotech (06955) rose nearly 4% BA1203 (shielded PD-1/IL-2) clinical trial approved to be developed for the treatment of various solid tumors

The Zhitong Finance App learned that Boan Biotech (06955) rose nearly 4%. As of press release, it had risen 3.75% to HK$2,625, with a turnover of HK$2.269,300.

According to the news, on September 14, Boan Biotech announced that the new drug clinical trial application (IND) for BA1203, the PD-1/IL-2 antibody cytokine precursor drug under development has been approved by the Drug Evaluation Center (CDE) of the China National Drug Administration to develop treatments for various solid tumors. According to the company's knowledge, the drug under development is the only PD-1/IL-2 molecule with high IL-2α receptor activity, shielding, and PD-1 blocking in the world.

As a next-generation IO candidate developed independently by the company, BA1203 combines the dual action mechanisms of PD-1 antibodies and IL-2 cytokines to simultaneously block immune checkpoints and activate local immunity in tumors. After being approved for clinical use, the company plans to conduct a multicenter, open phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of BA1203 in advanced solid tumor patients, further verify its advantages in terms of efficacy and safety, and explore its single-agent and combination therapy development paths to fully unleash the potential of BA1203 for differentiated treatment such as PD-1 target binding, immune pathway blocking, and tumor microenvironment immune activation.